A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
NCT05655520
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
153
Enrollment
INDUSTRY
Sponsor class
Stopped
Internal company decision
Conditions
Huntington's Disease
Interventions
DRUG:
SAGE-718
Sponsor
Supernus Pharmaceuticals, Inc.